Association of mouse Dlg4 (PSD-95) gene deletion and human DLG4 gene variation with phenotypes relevant to autism spectrum disorders and Williams' syndrome.

Objective: Research is increasingly linking autism spectrum disorders and other neurodevelopmental disorders to synaptic abnormalities ("synaptopathies"). PSD-95 (postsynaptic density-95, DLG4) orchestrates protein-protein interactions at excitatory synapses and is a major functional bridge interconnecting a neurexinneuroligin-SHANK pathway implicated in autism spectrum disorders.

Method: The authors characterized behavioral, dendritic, and molecular phenotypic abnormalities relevant to autism spectrum disorders in mice with PSD-95 deletion (Dlg4⁻(/)⁻).

Addressing shortfalls in TIA care in the UK: an economic perspective.

Objective: To estimate the clinical outcomes and costs associated with reconfiguring the management of TIA in the UK to offer patients rapid access to outpatient clinics for specialist assessment and treatment.

Methods: An economic deterministic model was run comparing two pathways--one arm representing current clinical care based on national guidelines and clinical practice and patient referral to a weekly outpatient clinic, and a revised care pathway replicating phase 2 of the EXPRESS study with patient referral to a daily outpatient clinic. The outcomes of the model were measured in terms of recurrent strokes avoided and net budget impact to secondary care.

Effects of temazepam on memory and psychomotor performance: a dose-response study.

In a randomised, three-period crossover study, psychomotor performance and memory were tested and mood assessed for 3 h after single doses of placebo (PL), 20 mg temazepam (T20) or 30 mg temazepam (T30) were given to six healthy females aged 21-23. A composite measure of psychomotor speed showed a dose-dependent slowing (Page's L trend test: p < 0.001; sign test PL vs T20 and T30 vs T20: p < 0.